top of page

FDA approves expanded indication for Pfizer’s Ibrance

The US Food and Drug Administration (FDA) has approved a new indication expanding the use of Ibrance (palbociclib), Pfizer’s metastatic breast cancer therapy.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page